P.H.M. van der Kuy

2.1k total citations
70 papers, 961 citations indexed

About

P.H.M. van der Kuy is a scholar working on Geriatrics and Gerontology, Cardiology and Cardiovascular Medicine and Economics and Econometrics. According to data from OpenAlex, P.H.M. van der Kuy has authored 70 papers receiving a total of 961 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Geriatrics and Gerontology, 11 papers in Cardiology and Cardiovascular Medicine and 9 papers in Economics and Econometrics. Recurrent topics in P.H.M. van der Kuy's work include Pharmaceutical Practices and Patient Outcomes (20 papers), Health Systems, Economic Evaluations, Quality of Life (8 papers) and SARS-CoV-2 and COVID-19 Research (7 papers). P.H.M. van der Kuy is often cited by papers focused on Pharmaceutical Practices and Patient Outcomes (20 papers), Health Systems, Economic Evaluations, Quality of Life (8 papers) and SARS-CoV-2 and COVID-19 Research (7 papers). P.H.M. van der Kuy collaborates with scholars based in Netherlands, Germany and Portugal. P.H.M. van der Kuy's co-authors include R. Janknegt, Yoeri F. L. Bemelmans, Nanne P. Kort, Martijn G.M. Schotanus, Cees Neef, Björn Winkens, Abraham A. Kroon, Hein A. W. van Onzenoort, Ralph Peeters and Peter W. de Leeuw and has published in prestigious journals such as New England Journal of Medicine, Clinical Infectious Diseases and Journal of Neurology Neurosurgery & Psychiatry.

In The Last Decade

P.H.M. van der Kuy

65 papers receiving 935 citations

Peers

Countries citing papers authored by P.H.M. van der Kuy

Since Specialization

Citations

This map shows the geographic impact of P.H.M. van der Kuy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P.H.M. van der Kuy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P.H.M. van der Kuy more than expected).

Fields of papers citing papers by P.H.M. van der Kuy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P.H.M. van der Kuy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P.H.M. van der Kuy. The network helps show where P.H.M. van der Kuy may publish in the future.

Co-authorship network of co-authors of P.H.M. van der Kuy

This figure shows the co-authorship network connecting the top 25 collaborators of P.H.M. van der Kuy. A scholar is included among the top collaborators of P.H.M. van der Kuy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P.H.M. van der Kuy. P.H.M. van der Kuy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Concomitant use of clopidogrel and proton pump inhibitors: A retrospective analysis of prescription behaviour 2025 ·British Journal of Clinical Pharmacology ·(unknown), (unknown), (unknown), Hanne van Ballegooijen, Rianne J. Zaal, P.H.M. van der Kuy	0
2	Stability of alglucosidase alfa in 0.9% sodium chloride for enzyme replacement therapy in patients with Pompe disease: insights from enzyme activity and cellular uptake measurements 2025 ·European Journal of Hospital Pharmacy ·(unknown), (unknown), Edwin H. Jacobs, Marianne Hoogeveen‐Westerveld, P.H.M. van der Kuy, (unknown)	0
3	Evaluation of a group-based online informed consent conversation (eConsent) in participants from a low-risk vaccination clinical trial 2024 ·Trials ·(unknown), Melvin Lafeber, Roos S. G. Sablerolles, (unknown), (unknown), (unknown), Leo G. Visser, Douwe F. Postma, Abraham Goorhuis, Wim J. R. Rietdijk, P.H.M. van der Kuy	0
4	Appropriate medication use in Dutch terminal care: study protocol of a multicentre stepped-wedge cluster randomized controlled trial (the AMUSE study) 2024 ·BMC Palliative Care ·(unknown), (unknown), Hein P. J. Visser, (unknown), Maurice J. D. L. van der Vorst, (unknown), (unknown), (unknown), (unknown), Esther Oomen‐de Hoop, Agnes van der Heide, P.H.M. van der Kuy, Carin C.D. van der Rijt, Eric C. T. Geijteman	1
5	Unraveling elements of value-based pricing from a pharmaceutical industry’s perspective: a scoping review 2024 ·Frontiers in Pharmacology ·(unknown), (unknown), P.H.M. van der Kuy	1
6	Prices of Orphan Drugs in Four Western European Countries Before and After Market Exclusivity Expiry: A Cross-Country Comparison of List Prices and Purchase Prices 2023 ·Applied Health Economics and Health Policy ·(unknown), (unknown), (unknown), (unknown), Martin J. Hug, Morten Baltzer Houlind, Pascal Paubel, P.H.M. van der Kuy, Carin A. Uyl‐de Groot	3
7	Digital Outcome Measurement to Improve Care for Patients With Immune-Mediated Inflammatory Diseases: Protocol for the IMID Registry 2023 ·JMIR Research Protocols ·(unknown), (unknown), (unknown), DirkJan Hijnen, Pascal H P de Jong, P.H.M. van der Kuy, Jan van Laar, C. Janneke van der Woude, Annelieke Pasma	2
8	Do junior doctors make more prescribing errors than experienced doctors when prescribing electronically using a computerised physician order entry system combined with a clinical decision support system? A cross-sectional study 2023 ·European Journal of Hospital Pharmacy ·(unknown), (unknown), P.H.M. van der Kuy, Walter W. van den Broek, Rianne J. Zaal, Floor van Rosse, Jorie Versmissen	1
9	Adjunctive Intravenous Immunoglobulin and Glucocorticoid Therapy in Severe Herpes Simplex Encephalitis with Excellent Outcome Begs for Larger Trials Evaluating Immunomodulatory Therapy 2023 ·American Journal of Case Reports ·George Sakoulas, (unknown), P.H.M. van der Kuy	0
10	Evaluation of a multifaceted medication review in older patients in the outpatient setting: a before-and-after study 2023 ·International Journal of Clinical Pharmacy ·(unknown), (unknown), P.H.M. van der Kuy, (unknown), (unknown), (unknown), Bart Spaetgens	2
11	Combatting the rising costs of cancer drugs; interventions from a university hospital’s perspective 2023 ·Frontiers in Pharmacology ·(unknown), (unknown), (unknown), P.H.M. van der Kuy, Stefan Sleijfer	3
12	Inpatients’ information needs about medication: A narrative systematic literature review 2023 ·Patient Education and Counseling ·(unknown), Heleen van der Sijs, (unknown), P.H.M. van der Kuy, Rianne J. Zaal	2
13	Barriers to patient enrolment in phase III cancer clinical trials: interviews with clinicians and pharmaceutical industry representatives 2022 ·BMJ Open ·(unknown), (unknown), James Kenneth Timmis, Monique E.M.M. Bos, Carin A. Uyl‐de Groot, P.H.M. van der Kuy	3
14	Understanding the association between sleep, shift work and COVID‐19 vaccine immune response efficacy: Protocol of the S‐CORE study 2021 ·Journal of Sleep Research ·(unknown), Gert Jan Lammers, Gijsbertus T. J. van der Horst, Inês Chaves, Rory D. de Vries, Corine H. GeurtsvanKessel, Birgit C. P. Koch, P.H.M. van der Kuy	16
15	Intranasal treatment of vitamin B12 deficiency in children 2019 ·European Journal of Pediatrics ·(unknown), P.H.M. van der Kuy, Tim G. de Meij, Marc A. Benninga, C. M. F. Kneepkens	17
16	Routine Assessment of Patient Index Data 3 (RAPID3) alone is insufficient to monitor disease activity in rheumatoid arthritis in clinical practice 2019 ·RMD Open ·(unknown), Alexandre Sepriano, P.H.M. van der Kuy, R. Janknegt, Ralph Peeters, Robert Landewé	13
17	Assessing the strengths and weaknesses of a computer assisted medication review in hospitalized patients 2017 ·Research Publications (Maastricht University) ·(unknown), (unknown), (unknown), R. Janknegt, Frans R.J. Verhey, Jos M. G. A. Schols, Fabienne Magdelijns, Coen D.A. Stehouwer, Björn Winkens, Wubbo J. Mulder, P.H.M. van der Kuy	4
18	Usually available clinical and laboratory data are insufficient for a valid medication review: A crossover study 2016 ·The journal of nutrition health & aging ·(unknown), (unknown), (unknown), P.H.M. van der Kuy, R. Janknegt, Frans R.J. Verhey, Jos M. G. A. Schols, Coen D.A. Stehouwer, Björn Winkens, Wubbo J. Mulder	5
19	Assessing Medication Adherence Simultaneously by Electronic Monitoring and Pill Count in Patients With Mild-to-Moderate Hypertension 2009 ·American Journal of Hypertension ·Hein A. W. van Onzenoort, (unknown), A. G. H. Kessels, Abraham A. Kroon, Cees Neef, P.H.M. van der Kuy, Peter W. de Leeuw	57
20	The relationship between reticulocyte hemoglobin content with C-reactive protein and conventional iron parameters in dialysis patients 2004 ·Journal of Nephrology ·C. M. Hackeng, (unknown), Marc M.H. Hermans, P.H.M. van der Kuy, (unknown), (unknown), Karly Hamulyák, Frank M. van der Sande, Karel M.L. Leunissen, Jeroen P. Kooman	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact